Novartis’ eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans to spin off the unit 2019.

Astellas Pharma Inc. plunked down nearly $109 million to snap up privately held Quethera Ltd. and the gene therapy company’s novel treatments for glaucoma and other ocular disorders.